Pfizer and BioNTech accomplished their request to the Meals and Drug Administration to approve their Covid-19 vaccine for kids as younger as 12, the businesses introduced Friday.
The businesses submitted Section III medical trial information to FDA as a supplemental software for his or her vaccine, which is already authorised for adults and kids as younger as 16. Within the new information, their vaccine was 100% efficient at stopping symptomatic Covid-19 in kids who acquired the vaccine as much as 4 months after their second dose. All kids who developed Covid-19 within the trial had acquired the placebo.
Background: The Pfizer-BioNTech Covid-19 vaccine is the one vaccine to obtain full FDA approval to this point. It is also the one vaccine out there for youthful kids. In Could, FDA licensed the vaccine for kids as younger as 12; it later licensed the vaccine for kids as younger as 5 in October.